Table of Contents
SWOT Analysis — 6
Pakistan Pharmaceutical Industry
SWOT — 6
Pakistan Political SWOT — 7
Pakistan Economic SWOT — 8
Pakistan Business Environment
SWOT — 9
Pharmaceutical Business Environment
Ratings — 10
Business Environment
Ranking — 10
Table: Asia Pacific Pharmaceutical Business
Environment Rankings For Q409 — 10
Limits Of Potential
Returns — 11
Risks To Realisation Of
Returns — 11
Pakistan – Market
Summary — 13
Regulatory Regime — 14
Intellectual Property Regime — 15
Shortcomings Of The
Intellectual Property Environment — 16
Table: Healthcare
And Pharmaceutical Companies That Are Members Of The American Business Council
Of Pakistan — 16
Counterfeit
Drugs — 17
Pricing and Reimbursement
Regime — 18
Recent Pricing and Reimbursement
Developments — 18
Industry Trends And
Developments — 21
Epidemiology — 21
Recent Public Health Developments — 22
Healthcare
System — 23
Table: Pakistan – Key Healthcare
Statistics, 2007 (‘000 people, unless otherwise
stated) — 24
Pharmaceutical
Sector — 25
Recent Pharmaceutical Sector
Developments — 25
Domestic Pharmaceutical
Industry — 26
Foreign Pharmaceutical
Industry — 27
Traditional
Medicine — 27
Retail Sector — 28
Research and Development — 29
International
Co-operation — 29
Medical Devices — 31
Industry Forecast Scenario — 33
Overall Market
Forecast — 33
Table: Pakistan – Drug Expenditure
Indicators, Historical Data and Forecasts — 34
Key Growth
Factors – Industry — 35
Table: Pakistan –
Health Expenditure Indicators, Historical Data and
Forecasts — 36
Key Growth Factors –
Macroeconomic — 37
Table: Pakistan - Economic Activity,
2006-2013 — 38
Prescription Market
Forecasts — 39
Table: Pakistan – Prescription Market
Indicators, Historical Data and Forecasts (PKRmn unless otherwise
stated) — 41
Patented Product Market
Forecast — 42
Table: Pakistan – Patented Drugs
Market Indicators, Historical Data and Forecasts — 43
Generic Drug Market Forecast — 44
Table: Pakistan –
Generic Drugs Market Indicators, Historical Data and
Forecasts — 45
OTC Market
Forecast — 46
Table: Pakistan – OTC Drugs Market
Indicators, Historical Data and Forecasts (PKRmn unless otherwise
stated) — 47
Pharmaceutical Trade
Forecasts — 48
Table: Pakistan – Pharmaceutical
Trade Indicators, Historical Data and Forecasts
(US$mn) — 49
Other Healthcare Data
Forecasts — 50
Table: Pakistan – Other Healthcare
Indicators, Historical Data and Forecasts (per ‘000 population, unless
otherwise stated) — 51
Key Risks To BMI’s Forecast
Scenario — 51
Competitive
Landscape — 52
Table: Pakistan’s Pharmaceutical
Market In Q406 — 52
Company
Monitor — 53
Leading Multinational
Manufacturers — 53
GlaxoSmithKline — 53
Pfizer — 56
Abbott Laboratories — 57
Novartis — 59
Sanofi-Aventis — 60
Merck & Co — 62
Wyeth — 63
Domestic Manufacturers — 65
Hilton Pharma — 65
Efroze Chemical
Industries — 66
Ferozsons
Laboratories — 67
Getz Pharma — 69
Pacific Pharmaceuticals — 71
Country Snapshot: Pakistan
Demographic Data — 73
Section 1:
Population — 73
Table: Demographic Indicators,
2005-2030 — 73
Table: Rural/Urban Breakdown,
2005-2030 — 74
Section 2: Education and
Healthcare — 74
Table: Education,
2002-2005 — 74
Table: Vital Statistics,
2005-2030 — 74
Table: Employment Indicators,
2001-2006 — 75
Section 3: Labour Market And Spending
Power — 76
Table: Consumer Expenditure, 2000-2012
(US$) — 76
Table: Average Annual Manufacturing Wages,
2000-2012 — 76
BMI Methodology — 77
How We Generate Our Pharmaceutical Industry Forecasts — 77
Pharmaceutical Business Environment Ratings
Methodology — 78
Ratings Overview — 78
Table: Pharmaceutical Business Environment Indicators — 79
Weighting — 80
Table: Weighting Of
Components — 80
Sources — 80
| 
View Cart
